文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎患者接受替诺福韦与恩替卡韦方案的肝细胞癌风险:个体患者数据Meta分析

Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis.
PubMed 文献 · J Hepatol · 2022-12-23

该个体患者数据Meta分析纳入来自韩国、台湾和香港的11项研究共42,939例接受替诺福韦二吡呋酯(TDF,n=6,979)或恩替卡韦(ETV,n=35,960)单药治疗的初治慢性乙型肝炎患者,比较两组肝细胞癌(HCC)风险。结果显示TDF组HCC风险显著低于ETV组(校正HR 0.77,95%CI 0.61-0.98,p=0.03),在HBeAg阳性等亚组中一致。结论认为TDF与较低的HCC风险相关,尤其HBeAg阳性患者,需更长随访以明确各亚组发病率差异。

要点

  • TDF组HCC风险显著低于ETV组(校正HR 0.77,95%CI 0.61-0.98,p=0.03)。
  • PSM分析中TDF组HCC风险显著低于ETV组(HR 0.73,95%CI 0.59-0.88,p<0.01)。
  • HBeAg阳性亚组TDF组HCC风险显著低于ETV组(HR 0.69,95%CI 0.49-0.97,p=0.03)。

核心结论

  • 在慢性乙型肝炎患者中,TDF与显著低于ETV的HCC风险相关,尤其在HBeAg阳性患者中。
  • 可能需要更长随访以更好地明确不同亚组中两种治疗之间HCC发病率的差异。

研究设计与样本

  • 个体患者数据Meta分析,检索截至2021年1月的已发表Meta分析、电子数据库和会议论文集。
  • 纳入来自韩国、台湾和香港的11项研究,共42,939例接受TDF(n=6,979)或ETV(n=35,960)单药治疗的初治慢性乙型肝炎患者,治疗至少1年。
  • 使用多变量Cox比例风险模型比较两组HCC风险,并通过倾向性评分匹配(PSM)、倾向性评分加权(PSW)及亚组分析探索治疗效果一致性。

主要发现

  • TDF组HCC风险显著低于ETV组(校正HR 0.77,95%CI 0.61-0.98,p=0.03)。
  • PSM分析中TDF组HCC风险显著低于ETV组(HR 0.73,95%CI 0.59-0.88,p<0.01)。
  • PSW分析中TDF组HCC风险低于ETV组但未达统计学显著(HR 0.83,95%CI 0.67-1.03,p=0.10)。
  • ≥50岁亚组TDF组HCC风险低于ETV组(HR 0.76,95%CI 0.58-1.00,p<0.05)。
  • 男性亚组TDF组HCC风险显著低于ETV组(HR 0.74,95%CI 0.58-0.96,p=0.02)。

关键数值与推荐

  • HCC风险比较采用校正HR 0.77(95%CI 0.61-0.98,p=0.03),指向TDF组低于ETV组。
  • PSM分析HR 0.73(95%CI 0.59-0.88,p<0.01),TDF组低于ETV组。
  • PSW分析HR 0.83(95%CI 0.67-1.03,p=0.10),TDF组低于ETV组但未达统计学显著。
  • 亚组HR:≥50岁0.76(95%CI 0.58-1.00,p<0.05)、男性0.74(95%CI 0.58-0.96,p=0.02)、HBeAg阳性0.69(95%CI 0.49-0.97,p=0.03)、非糖尿病0.79(95%CI 0.63-1.00,p<0.05),均为TDF组低于ETV组。

临床怎么用

  • 作者认为医疗保健提供者在确定慢性乙型肝炎患者的最佳治疗方案时应考虑这些发现。
  • 作者认为这些发现可被考虑用于确保慢性乙型肝炎治疗指南保持相关性。

局限性

  • 原文结论指出可能需要更长随访以更好地明确不同亚组中两种治疗之间HCC发病率的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The comparative risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) remains controversial. In this individual patient data (IPD) meta-analysis, we aimed to compare HCC risk between the two drugs and identify subgroups who may benefit more from one treatment than the other. METHODS: Published meta-analyses, electronic databases and congress proceedings were searched to identify eligible studies through January 2021. We compared HCC risk between the two drugs using a multivariable Cox proportional hazards model with anonymised IPD from treatment-naïve patients with CHB receiving TDF or ETV for ≥1 year. Treatment effect consistency was explored in propensity score matching (PSM), weighting (PSW) and subgroup analyses for age, sex, hepatitis B e-antigen (HBeAg) positivity, cirrhosis and diabetes status. RESULTS: We included 11 studies from Korea, Taiwan and Hong Kong involving 42,939 patients receiving TDF (n = 6,979) or ETV (n = 35,960) monotherapy. Patients receiving TDF had significantly lower HCC risk (adjusted hazard ratio [HR] 0.77; 95% CI 0.61-0.98; p = 0.03). Lower HCC risk with TDF was consistently observed in PSM (HR 0.73; 95% CI 0.59-0.88; p <0.01) and PSW (HR 0.83; 95% CI 0.67-1.03; p = 0.10) analyses and in all subgroups, with statistical significance in the ≥50 years of age (HR 0.76; 95% CI 0.58-1.00; p <0.05), male (HR 0.74; 95% CI 0.58-0.96; p = 0.02), HBeAg-positive (HR 0.69; 95% CI 0.49-0.97; p = 0.03) and non-diabetic (HR 0.79; 95% CI 0.63-1.00; p <0.05) subgroups. CONCLUSION: TDF was associated with significantly lower HCC risk than ETV in patients with CHB, particularly those with HBeAg positivity. Longer follow-up may be needed to better define incidence differences between the treatments in various subgroups. IMPACT AND IMPLICATIONS: Previous aggregate data meta-analyses have reported inconsistent conclusions on the relative effectiveness of tenofovir disoproxil fumarate and entecavir in reducing hepatocellular carcinoma risk in patients with chronic hepatitis B (CHB). This individual patient data meta-analysis on 11 studies involving 42,939 patients from Korea, Taiwan and Hong Kong suggested that tenofovir disoproxil fumarate-treated patients have a significantly lower hepatocellular carcinoma risk than entecavir-treated patients, which was observed in all subgroups of clinical interest and by different analytical methodologies. These findings should be taken into account by healthcare providers when determining the optimal course of treatment for patients with CHB and may be considered in ensuring that treatment guidelines for CHB remain pertinent.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Choi WM, Yip TC, Wong GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol. 2022. PMID: 36572349. doi:10.1016/j.jhep.2022.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。